I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 55% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 55% ± 25% |
Insufficient scRNA-seq data for expression of SERPIND1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 18856.49 | 226 / 226 | 97% | 968.13 | 395 / 406 |
| lung | 89% | 119.89 | 517 / 578 | 53% | 13.31 | 610 / 1155 |
| stomach | 88% | 34.57 | 315 / 359 | 34% | 2.99 | 96 / 286 |
| bladder | 81% | 97.29 | 17 / 21 | 34% | 3.13 | 169 / 504 |
| uterus | 91% | 227.55 | 155 / 170 | 9% | 0.46 | 42 / 459 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.26 | 1 / 1 |
| ovary | 94% | 139.11 | 169 / 180 | 1% | 0.08 | 5 / 430 |
| thymus | 77% | 26.07 | 501 / 653 | 11% | 0.53 | 65 / 605 |
| esophagus | 63% | 24.24 | 910 / 1445 | 21% | 0.62 | 39 / 183 |
| pancreas | 38% | 8.95 | 125 / 328 | 44% | 3.93 | 78 / 178 |
| brain | 71% | 64.76 | 1870 / 2642 | 8% | 0.46 | 59 / 705 |
| breast | 72% | 48.49 | 330 / 459 | 3% | 0.15 | 36 / 1118 |
| adipose | 72% | 32.69 | 861 / 1204 | 0% | 0 | 0 / 0 |
| adrenal gland | 62% | 25.33 | 160 / 258 | 7% | 0.22 | 16 / 230 |
| heart | 67% | 54.02 | 577 / 861 | 0% | 0 | 0 / 0 |
| intestine | 32% | 6.12 | 312 / 966 | 35% | 3.05 | 182 / 527 |
| kidney | 53% | 10.90 | 47 / 89 | 4% | 2.02 | 38 / 901 |
| prostate | 48% | 11.00 | 117 / 245 | 4% | 0.20 | 19 / 502 |
| peripheral blood | 50% | 51.23 | 461 / 929 | 0% | 0 | 0 / 0 |
| spleen | 47% | 25.78 | 114 / 241 | 0% | 0 | 0 / 0 |
| skin | 22% | 4.64 | 390 / 1809 | 15% | 1.35 | 69 / 472 |
| blood vessel | 35% | 11.79 | 464 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 18% | 3.42 | 141 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.10 | 1 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.06 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006935 | Biological process | chemotaxis |
| GO_0007596 | Biological process | blood coagulation |
| GO_0010951 | Biological process | negative regulation of endopeptidase activity |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005576 | Cellular component | extracellular region |
| GO_0008201 | Molecular function | heparin binding |
| GO_0004866 | Molecular function | endopeptidase inhibitor activity |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| Gene name | SERPIND1 |
| Protein name | Serpin peptidase inhibitor, clade D (Heparin cofactor), member 1 Heparin cofactor 2 (Heparin cofactor II) (HC-II) (Protease inhibitor leuserpin-2) (HLS2) (Serpin D1) |
| Synonyms | HCF2 |
| Description | FUNCTION: Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner. .; FUNCTION: Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils. . |
| Accessions | ENST00000406799.1 P05546 ENST00000215727.10 Q8IVC0 |
